CHeBA Visiting Lecture Series presents Professor Ron Petersen of Mayo Clinic, for his talk:
Diagnosing Alzheimer’s Disease in the Biomarker Era: Promises and Pitfalls
The presentation will be followed by a live Q&A session with Professor Petersen
The landscape for making the diagnosis of Alzheimer’s Disease (AD) is changing. Formerly, the diagnosis of AD was a clinical-pathological process relying on a typical clinical presentation and confirmed at autopsy. With the advent of AD biomarkers, the situation has evolved. Now with AD imaging or fluid biomarkers, conclusions about an AD component can be inferred in life. However, this approach presents concerns. Does this mean that AD clinical research without biomarkers is invalid? What about pathological co-morbidities? This discussion will address these issues and attempt to look at the future of AD research and clinical practice.
Ronald C. Petersen, M.D., Ph.D., focuses on investigations of cognition in normal aging, mild cognitive impairment and dementia. Dr. Petersen and his colleagues evaluate cognitive changes in normal aging as well as in a variety of disorders involving impairment in cognition, such as Alzheimer's disease, frontotemporal lobar degeneration and Lewy body dementia. Dr. Petersen directs the Mayo Clinic Alzheimer's Disease Research Center and the Mayo Clinic Study of Aging, both of which involve the study and characterization of aging individuals over time with an emphasis on neuroimaging and biomarkers.